Novo Nordisk set to announce hemophilia pipeline at ASH
December 1, 2014; Posted by: WeBleed staff
Novo Nordisk will present abstracts concerning upcoming bleeding disorders pipeline at annual meeting.
Pharmaceutical company Novo Nordisk is set to release data on upcoming hemophilia and bleeding disorders medications at the 56th Annual Meeting of the American Society of Hematology (ASH) from December 6–9 in San Francisco, California. Topics will include hemophilia A and B, as well as the impact and unmet needs of Glanzmann’s Thrombasthenia. Overall, Novo Nordisk will unveil 11 abstracts.and pipeline at the
“Novo Nordisk is excited to present such a robust data set at this year’s ASH Annual Meeting and to continue to make important contributions to the body of scientific knowledge available on hemophilia and other rare bleeding disorders,” said Stephanie Seremetis, M.D., CMO and CVP, Hemophilia, Novo Nordisk, in a release from MarketWatch. “We seek to continuously advance the development of new therapies to benefit the bleeding disorders community.”
The ASH Annual Meeting is always filled with new and exciting information and WeBleed will post updates as they become available.
Photo Credit – Novo Nordisk
webleed.org – your source for bleeding news!
